Robert Zeiser
Hugstetter Str, 55 79106
Freiburg, BW 79106, Germany
Freiburg, BW 79106, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 364 publications
Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.
Journal: Transplantation and cellular therapy
Published: August 26, 2026
Anti-inflammatory approaches in cancer immunotherapy-induced autoimmunity.
Journal: EULAR rheumatology open
Published: August 20, 2026
Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.
Journal: The Journal of clinical investigation
Published: August 04, 2026
MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.
Journal: medRxiv : the preprint server for health sciences
Published: July 29, 2026
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2026
Spatial Transcriptomics reveals a T cell-mediated microglial activation axis of neurodegeneration following immune checkpoint inhibition.
Journal: bioRxiv : the preprint server for biology
Published: June 22, 2026
Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: the association of JACIE accreditation/preparation and center volume.
Journal: Haematologica
Published: May 21, 2026
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022.
Journal: British journal of haematology
Published: May 15, 2026
Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis.
Journal: Transplantation and cellular therapy
Published: May 08, 2026
Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis.
Journal: Transplantation and cellular therapy
Published: May 08, 2026
Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.
Journal: Bone marrow transplantation
Published: April 27, 2026
The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.
Journal: Bone marrow transplantation
Published: April 03, 2026
Last Updated: 09/26/2026